• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, May 14, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Flinders University to trial SLT for high risk glaucoma patients in world first

by Staff Writer
August 2, 2023
in Eye disease, Glaucoma, Local, News, Ophthalmic insights, Research
Reading Time: 3 mins read
A A
Flinders University Professor of Ophthalmology Jamie Craig

Chief investigator Professor Jamie Craig has been awarded over $1.7 million for the project.

Share on FacebookShare on Twitter

In a world first, ophthalmology experts at Flinders University will trial early intervention treatment, selective laser trabeculoplasty (SLT), to prevent people at high risk of glaucoma from developing loss of sight from the disease.

Chief investigator Professor Jamie Craig, Matthew Flinders Distinguished Professor at the College of Medicine and Public Health, has been awarded over $1.7 million to explore the use of early intervention to prevent glaucoma related vision loss for those at risk.

The trial will use SLT that has been proven to slow disease progression by lowering intraocular pressure. The trial will determine the effectiveness and suitability of using SLT laser as an early intervention to prevent the onset of visual loss from glaucoma.

“We have developed a tool that can identify individuals who are deemed at high risk of losing their vision from glaucoma, however there is still a major gap between identifying them and how they may be safely treated,” Craig said.

He said early detection and treatment of those most at risk of vision loss is fundamental to reducing the disease burden for patients and the health care system.

“This clinical trial will generate high-quality evidence to determine the effectiveness of a more timely delivery of laser for high-risk individuals. If effective, this will reduce visual issues and blindness from glaucoma which will improve their quality of life, allow them to continue working and driving, reduce their risk of falls and lead to cost savings for the health system,” he said.

The $1.7 million research project will use a randomised controlled trial of 500 genetically at-risk glaucoma suspects to determine the effectiveness of early laser treatment in preventing loss of vision.

After receiving the laser treatment, participants will be monitored twice a year over a two-year period.

“Insights gained from this trial will have immediate implications for the monitoring and treatment of high-risk glaucoma patients, with the aim of preventing progressive vision loss and blindness both in Australia and internationally,” Craig said.

The new project also involves other researchers from Flinders University, University of Tasmania, Maquarie University, The University of Adelaide, The Garvan Institute of Medical Research, The Council of the Queensland Institute of Medical Research, University of New South Wales, and The George Institute for Global Health.

Craig has made important discoveries on the genetic basis of glaucoma using a pioneering International Registry of cases of vision loss. This approach led to genome-wide association studies identifying multiple genes associated with glaucoma susceptibility. These discoveries are now moving into the clinic as risk profiling for individuals becomes a reality.

This project follows on from previous research by Craig developing a glaucoma polygenic risk score (PRS) which effectively identifies individuals at high risk of becoming blind from glaucoma.

It found that PRS is highly predictive of future vision loss and that new monitoring and treatment strategies such as the pre-emptive laser treatment are required.

More reading

Genetic discovery could accelerate glaucoma treatment, but more study participants needed

Macquarie ophthalmology researchers first to find link between neuroserpin and glaucoma

Can genes expose more glaucoma in the population?

Related Posts

Anxious patients can be more restless during surgery, risking complications. Image: Vision Eye Institute.

Taming the tremors in refractive surgery

by Staff Writer
May 13, 2025

Refractive surgery, while a life-changing procedure for many, can be a significant source of anxiety for patients. Anecdotally, we observed...

There were 1,156 allegations to Ahpra of ‘boundary violations’ in 2023-24. 
Image: Pormezz/Shutterstock.com.

Ahpra reforms: Sexual misconduct on register permanently

by Staff Writer
May 13, 2025

Optometrists, ophthalmologists and other registered Australian practitioners proven to have committed sexual misconduct will have this information permanently published against...

Each year, Vision Australia helps between 80 and 100 people with blindness and low vision into employment.  Image: Vision Australia.

Vision Australia – working to give people a future and a ‘fair go’

by Rob Mitchell
May 12, 2025

A diagnosis of permanent vision loss is not the end. At Vision Australia it’s the start of a new journey...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited